Stockscreener 앱 받기
17.82
4.58%
0.78
전일 마감가:
$17.04
열려 있는:
$17.16
하루 거래량:
3.55M
Relative Volume:
1.15
시가총액:
$13.27B
수익:
$220.00K
순이익/손실:
$-746.08M
주가수익비율:
-17.69
EPS:
-1.0074
순현금흐름:
$-211.81M
1주 성능:
+1.42%
1개월 성능:
+7.61%
6개월 성능:
-11.61%
1년 성능:
-3.15%
1일 변동 폭
$17.14
$17.90
1주일 범위
$16.87
$17.90
52주 변동 폭
$15.55
$36.91
Summit Therapeutics Inc Stock (SMMT) Company Profile
명칭
Summit Therapeutics Inc
전화
305-203-2034
주소
601 BRICKELL KEY DRIVE, MIAMI
SMMT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SMMT
Summit Therapeutics Inc
|
17.82 | 12.69B | 220.00K | -746.08M | -211.81M | -1.0074 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Summit Therapeutics Inc Stock (SMMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-09-17 | 개시 | Barclays | Underweight |
| 2025-09-04 | 개시 | Guggenheim | Buy |
| 2025-08-19 | 개시 | Piper Sandler | Neutral |
| 2025-07-01 | 개시 | UBS | Buy |
| 2025-06-11 | 개시 | Leerink Partners | Underperform |
| 2025-03-26 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-12 | 개시 | Evercore ISI | Outperform |
| 2025-02-28 | 개시 | Goldman | Buy |
| 2025-01-08 | 개시 | Truist | Buy |
| 2024-12-11 | 개시 | Wells Fargo | Overweight |
| 2024-12-06 | 개시 | Jefferies | Buy |
| 2024-11-04 | 개시 | JMP Securities | Mkt Outperform |
| 2024-09-27 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-08-12 | 개시 | H.C. Wainwright | Buy |
| 2024-05-07 | 개시 | Citigroup | Buy |
| 2024-03-26 | 개시 | Stifel | Buy |
| 2018-06-28 | 다운그레이드 | Janney | Buy → Neutral |
| 2018-05-02 | 개시 | Janney | Buy |
| 2018-04-12 | 재확인 | Needham | Buy |
| 2018-02-13 | 개시 | BTIG Research | Buy |
| 2018-01-04 | 개시 | SunTrust | Buy |
| 2017-12-01 | 재개 | H.C. Wainwright | Buy |
| 2016-11-16 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-10-05 | 재확인 | Needham | Buy |
| 2016-09-16 | 개시 | H.C. Wainwright | Buy |
| 2015-03-30 | 개시 | Needham | Buy |
| 2015-03-30 | 개시 | Oppenheimer | Outperform |
모두보기
Summit Therapeutics Inc 주식(SMMT)의 최신 뉴스
Is Summit Therapeutics Inc. stock a defensive play in 20252025 Price Momentum & Free Community Consensus Stock Picks - Улправда
How Summit Therapeutics Inc. stock compares to industry benchmarks2025 Big Picture & Long Hold Capital Preservation Plans - ulpravda.ru
Will Summit Therapeutics Inc. stock outperform Dow Jones indexPortfolio Return Report & AI Powered Buy and Sell Recommendations - ulpravda.ru
How Summit Therapeutics Inc. stock valuations compare to rivalsJuly 2025 Opening Moves & Community Verified Trade Alerts - DonanımHaber
Can Summit Therapeutics Inc. stock continue upward trendJuly 2025 Rallies & Stepwise Entry and Exit Trade Signals - Улправда
Summit Therapeutics stock rating reiterated by Cantor Fitzgerald - Investing.com Canada
Gap Down: How Summit Therapeutics Inc. stock valuations compare to rivalsWeekly Market Summary & Low Risk Profit Maximizing Plans - DonanımHaber
Gains Recap: Will Summit Therapeutics Inc. stock outperform Dow Jones indexJuly 2025 WrapUp & Weekly Stock Breakout Alerts - Улправда
Barclays Upgrades Summit Therapeutics (SMMT) - Nasdaq
Barclays Upgrades SMMT, Raises Price Target to $18 | SMMT Stock News - GuruFocus
Summit Therapeutics (NASDAQ:SMMT) Upgraded by Barclays to Equal Weight Rating - MarketBeat
Summit Therapeutics stock rating upgraded by Barclays on BLA timeline - Investing.com UK
Summit Therapeutics (NASDAQ:SMMT) Stock Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat
Trading Systems Reacting to (SMMT) Volatility - news.stocktradersdaily.com
Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development - Yahoo Finance
Citi asserts buy rating on Summit Therapeutics Inc. (SMMT) on pipeline development - MSN
Has Summit Therapeutics Rally Left Enough Upside After 448.6% Surge and DCF Upswing? - Yahoo Finance
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run - Finviz
U.S. Markets Ended Tuesday Mixed As Galaxy Digital Led, Summit Therapeutics Lagged - Barron's
Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility - ts2.tech
Summit Therapeutics (NASDAQ:SMMT) Shares Down 4.4%Here's Why - MarketBeat
Norges Bank Invests $29.58 Million in Summit Therapeutics PLC $SMMT - MarketBeat
New York State Common Retirement Fund Buys 227,513 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
Schroder Investment Management Group Sells 89,090 Shares of Summit Therapeutics PLC $SMMT - MarketBeat
State Board of Administration of Florida Retirement System Boosts Stake in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? - Finviz
Trading Near Its 52-Week Low, Is Summit Therapeutics a Good Stock to Buy Right Now? - The Motley Fool
Why analysts upgrade Summit Therapeutics Inc. stockJuly 2025 Earnings & Weekly Chart Analysis and Guides - Newser
Summit Therapeutics Inc. (SMMT) Options Chain - Yahoo! Finance Canada
1 Reason I'll Never Sell Vertex Pharmaceuticals Stock - AOL.com
Summit Therapeutics (NASDAQ:SMMT) Trading 9.2% HigherShould You Buy? - MarketBeat
Can Summit Therapeutics Inc. stock maintain operating marginsWeekly Gains Report & AI Powered Market Trend Analysis - Newser
Summit Therapeutics Earnings Notes - Trefis
Don't Buy Summit Therapeutics Until This Big Thing Happen - Nasdaq
Widening Q3 Losses and Insider Buying Might Change The Case For Investing In Summit Therapeutics (SMMT) - Yahoo Finance
Summit Therapeutics (SMMT): Valuation Check After Weak Q3 2025 Results and Insider Share Purchases - Yahoo Finance
How Summit Therapeutics Inc. (SMMT) Affects Rotational Strategy Timing - news.stocktradersdaily.com
SMMT: Four positive phase 3 trials and accelerated timelines position the pipeline for NSCLC market leadership - TradingView
XTX Topco Ltd Makes New $925,000 Investment in Summit Therapeutics PLC $SMMT - MarketBeat
2 Monster Stocks in the Making to Buy and Hold - The Globe and Mail
Summit Therapeutics: InvestingPro’s Fair Value model predicted 37% downside By Investing.com - Investing.com Nigeria
Summit Therapeutics (SMMT) Stock Analysis Report | Financials & Insights - Benzinga
33,096 Shares in Summit Therapeutics PLC $SMMT Acquired by Inceptionr LLC - MarketBeat
Rhenman & Partners Asset Management AB Makes New Investment in Summit Therapeutics PLC $SMMT - MarketBeat
Summit Therapeutics PLC (NASDAQ:SMMT) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
WE Convention 2025: Dr. Maky Zanganeh, Co-CEO and President, Summit Therapeutics - Entrepreneur
January 2026 Options Now Available For Summit Therapeutics (SMMT) - Nasdaq
Summit Therapeutics Inc. (SMMT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Summit Therapeutics Inc (SMMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Summit Therapeutics Inc 주식 (SMMT) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Oct 21 '25 |
Buy |
18.74 |
26,680 |
499,983 |
76,680 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 10 '25 |
Buy |
17.68 |
333,394 |
5,894,406 |
556,088,090 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
Sep 11 '25 |
Buy |
18.07 |
5,000 |
90,350 |
556,093,090 |
| Zanganeh Mahkam | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
| DUGGAN ROBERT W | Co-Chief Executive Officer |
May 30 '25 |
Option Exercise |
2.64 |
74,545 |
196,799 |
555,754,696 |
0.44%
자본화:
|
볼륨(24시간):